EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

A Pilot Real-life Study Opioid Induced Constipation in Neoplastic Patients Admitted to Internal Medicine Ward. Outcome of Naldemedine Therapy According to Available Guidelines

Chiara Valentina Luglio, Agostino Di Ciaula, Silvia Sozzi, Claudia Conforti, Gianluca Bitonto, Piero Portincasa, Oic-Ba Study Group

Journal of Gastrointestinal and Liver Diseases · 27.06.2026 · 35 (2) · 167-172

DOI: 10.15403/jgld-6733 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 27.06.2026. Verfasst von Chiara Valentina Luglio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine 'A. Murri' and Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari 'Aldo …. Hauptthemen laut MEDLINE: Analgesics, Opioid, Opioid-Induced Constipation, Cancer Pain, Naltrexone. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: The use of opioids has expanded significantly worldwide in patients with cancer-related pain. Therefore, opioid-induced constipation (OIC) is emerging as one of the most frequent and distressing gastrointestinal side effects. Despite the high prevalence, OIC is frequently underdiagnosed and inadequately managed, with critical effects on the quality of life of patients.

Methods

The present study assessed the real-life prevalence of opioid use and OIC in 316 consecutive cancer patients hospitalized in an Internal Medicine ward and evaluated the outcomes following PEG or naldemedine during hospitalization. When OIC was diagnosed (Rome IV criteria), all patients underwent polyethylene glycol (PEG). Naldemedine was subsequently administered in refractory OIC.

Results

A total of 82 patients (26% of admissions) were assuming opioids for cancer pain, with constipation diagnosed in 62% and 24% of patients with or without opioid treatment, respectively. The risk of OIC was higher during combined opioids than in monotherapy, and fentanyl was associated with the highest OIC prevalence. Among patients with OIC, 47% responded to polyethylene glycol (PEG), whereas 52.9% started naldemedine 200 micrograms/day for a refractory OIC, with subsequent improvement in 59.3% of cases.

Conclusions

The prevalence of opioid use and OIC is relevant among hospitalized cancer patients. The systematic adoption of standardized diagnostic tools can improve recognition and the clinical management in patients with OIC, in particular in case of refractory OIC. It is essential to increase awareness on this condition and to implement management pathways based on existing guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidOpioid-Induced ConstipationCancer PainNaltrexoneNarcotic AntagonistsInternal MedicineConstipationHumansFemalePilot ProjectsMaleAgedMiddle AgedTreatment OutcomePolyethylene GlycolsPractice Guidelines as TopicPrevalenceAged, 80 and overRisk FactorsGuideline AdherencePatient Admission

Substanzen

Analgesics, OpioidnaldemedineNaltrexoneNarcotic AntagonistsPolyethylene Glycols

Autor:innen und Institutionen

  • Division of Internal Medicine 'A. Murri' and Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari 'Aldo Moro'. chiarav.luglio@gmail.com.
  • Division of Internal Medicine "A. Murri" and Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy. agostinodiciaula@tiscali.it.
  • Division of Internal Medicine 'A. Murri' and Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari 'Aldo Moro'. silviasozzi93@gmail.com.
  • Division of Internal Medicine 'A. Murri' and Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari 'Aldo Moro'. c.conforti@studenti.uniba.it.
  • Division of Internal Medicine 'A. Murri' and Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari 'Aldo Moro'. g.bitonto@studenti.uniba.it.
  • Division of Internal Medicine 'A. Murri' and Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari 'Aldo Moro'. piero.portincasa@uniba.it.

Zitieren

APA

Luglio, C. V., Di Ciaula, A., Sozzi, S., Conforti, C., Bitonto, G., Portincasa, P., & Study Group, O. B. (2026). A Pilot Real-life Study Opioid Induced Constipation in Neoplastic Patients Admitted to Internal Medicine Ward. Outcome of Naldemedine Therapy According to Available Guidelines. Journal of Gastrointestinal and Liver Diseases, 35(2), 167-172. https://doi.org/10.15403/jgld-6733

Vancouver

Luglio CV, Di Ciaula A, Sozzi S, Conforti C, Bitonto G, Portincasa P, et al. A Pilot Real-life Study Opioid Induced Constipation in Neoplastic Patients Admitted to Internal Medicine Ward. Outcome of Naldemedine Therapy According to Available Guidelines. Journal of Gastrointestinal and Liver Diseases. 2026;35(2):167-172. doi:10.15403/jgld-6733

BibTeX
@article{Luglio2026,
  author = {Luglio, Chiara Valentina and Di Ciaula, Agostino and Sozzi, Silvia and Conforti, Claudia and Bitonto, Gianluca and Portincasa, Piero and Study Group, Oic-Ba},
  title = {A Pilot Real-life Study Opioid Induced Constipation in Neoplastic Patients Admitted to Internal Medicine Ward. Outcome of Naldemedine Therapy According to Available Guidelines},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2026},
  volume = {35},
  number = {2},
  pages = {167--172},
  doi = {10.15403/jgld-6733}
}
Kostenlos starten →